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Abstract
Spinal and bulbar muscular atrophy (SBMA) is a neuromuscular disorder caused by polyglutamine expansion in the androgen
receptor (AR) and characterized by the loss of lower motor neurons. Here we investigated pathological processes occurring in
muscle biopsy specimens derived from SBMA patients and, as controls, age-matched healthy subjects and patients suffering
from amyotrophic lateral sclerosis (ALS) and neurogenic atrophy. We detected atrophic fibers in the muscle of SBMA, ALS and
neurogenic atrophy patients. In addition, SBMA muscle was characterized by the presence of a large number of hypertrophic
fibers, with oxidative fibers having a larger size compared with glycolytic fibers. Polyglutamine-expanded AR expression was
decreased in whole muscle, yet enriched in the nucleus, and localized to mitochondria. Ultrastructural analysis revealed
myofibrillar disorganization and streaming in zones lacking mitochondria and degenerating mitochondria. Using molecular
(mtDNA copy number), biochemical (citrate synthase and respiratory chain enzymes) and morphological (dark blue area in
nicotinamide adenine dinucleotide-stained muscle cross-sections) analyses, we found a depletion of the mitochondria asso-
ciated with enhanced mitophagy. Mass spectrometry analysis revealed an increase of phosphatidylethanolamines and phos-
phatidylserines in mitochondria isolated from SBMA muscles, as well as a 50% depletion of cardiolipin associated with
decreased expression of the cardiolipin synthase gene. These observations suggest a causative link between nuclear
polyglutamine-expanded AR accumulation, depletion of mitochondrial mass, increased mitophagy and altered mitochon-
drial membrane composition in SBMA muscle patients. Given the central role of mitochondria in cell bioenergetics, thera-
peutic approaches toward improving the mitochondrial network are worth considering to support SBMA patients.
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Introduction
Spinal and bulbar muscular atrophy (SBMA), also named
Kennedy’s disease, is a neuromuscular disorder characterized
by the late-onset and progressive loss of motor neurons from
the brainstem and spinal cord, together with skeletal muscle
weakness, fasciculations and atrophy (1). In addition to neuro-
muscular symptoms, SBMA patients develop endocrine and
non-neuronal symptoms (2). SBMA is linked to CAG expansions
in the exon 1 of the gene coding for the androgen receptor (AR)
(3). In healthy subjects, this polyglutamine-encoding CAG trinu-
cleotide tandem repeat has a length of no more than 36 repeats,
and expansions over 38 cause disease. SBMA belongs to the
family of polyglutamine diseases, which also includes
Huntington’s disease (HD), dentatorubral-pallidoluysian atro-
phy (DRPLA) and spinocerebellar ataxia (SCA) type 1, 2, 3, 6, 7
and 17 (reviewed by 4). SBMA is a sex-specific disease with full
manifestations restricted to males. The sex specificity of SBMA
is owing to the higher serum levels of androgens in males com-
pared with females (5), and is also observed in transgenic and
knock-in mice expressing the polyglutamine-expanded AR
(5–8). Moreover, a strikingly androgen-dependent phenotype
manifests in transgenic flies expressing the polyglutamine-
expanded AR, which develop signs of neurodegeneration only if
fed a food containing androgens (9–11). Consistent with the
androgen-dependent nature of SBMA, surgical and pharmaco-
logical castration of transgenic mice reduced disease manifest-
ations, whereas treatment of female transgenic mice with
androgens induced neurodegeneration (6,7,12). Although treat-
ment of SBMA patients with anti-androgens exerts some benefi-
cial effects in clinical trials (13,14), the applicability of this
approach is limited by intrinsic side-effects.
Emerging evidence supports a key role for skeletal muscle
in SBMA pathogenesis (15). Expression of polyglutamine-
expanded AR in muscle is necessary and sufficient to cause dis-
ease. Indeed, the expression of polyglutamine-expanded AR in
all tissues, except for skeletal muscle, prevented disease mani-
festations in transgenic mice (16). Moreover, knock-down of
polyglutamine-expanded AR in peripheral tissues, including
skeletal muscle, ameliorated the phenotype of SBMA mice (17).
On the other hand, overexpression of non-expanded AR solely
in muscle resulted in a phenotype reminiscent of SBMA (18).
Analysis of muscle pathology in SBMA patients revealed the
presence of neurogenic atrophy, such as angulated atrophic
fibers and fiber-type grouping, and signs of myopathy, including
fiber splitting, increased presence of central nuclei, and degen-
eration of fibers (19,20). In addition, SBMA muscles are charac-
terized by the presence of hypertrophic fibers (20), a feature that
is observed also in the skeletal muscle of transgenic SBMA mice
at late stage of disease (21). In SBMA knock-in mice, muscles
composed of both glycolytic and oxidative fibers, such as the
quadriceps, are more severely affected then muscles mainly
composed of oxidative fibers. Muscles composed of glycolytic
and oxidative fibers undergo a metabolic switch toward an oxi-
dative phosphorylation, a metabolic alteration that precedes de-
nervation and is likely to result from intrinsic pathogenic
processes occurring in these muscles (22). These metabolic al-
terations in knock-in SBMA mice were associated with mito-
chondrial abnormalities, induction of protein turnover,
activation of mechanistic target of rapamycin (mTOR) signaling,
and induction of autophagy at late stages of disease. While ana-
lysis of skeletal muscle in animal models of SBMA has been ex-
tensively reported, analysis of muscle pathology in SBMA
patients is missing. Using skeletal muscle biopsies derived from
SBMA patients, we investigated pathological processes underly-
ing muscle weakness and wasting in SBMA patients. We found
that polyglutamine-expanded AR accumulated in the nucleus
and mitochondria of mature myotubes. Moreover, SBMA
muscles were characterized by a reduction in mitochondrial
mass, aberrant mitochondrial morphology, degenerating mito-
chondria with either a dense matrix or dilated-hypodense ma-
trix and swelling, decreased mtDNA and citrate synthase (CS)
activity, and enhanced autophagy and mitophagy. Finally,
SBMA muscle mitochondria presented with altered mitochon-
drial membrane lipid composition and downregulation of cardi-
olipin synthase expression.
Results
Increased atrophy and hypertrophy indexes in the
quadriceps muscle of SBMA patients
To investigate in detail pathological processes occurring in the
muscle of SBMA patients, we collected biopsy specimens from
the quadriceps femoris of SBMA patients with 41–49 CAG re-
peats and age- and gender-matched control subjects
(Supplementary Material, Table S1). Using hematoxylin and
eosin (H&E) analysis, we detected signs of neurogenic atrophy
together with myopathic changes, such as fiber splitting and
increased internal nuclei (Fig. 1A; Supplementary Material, S1),
as others and we have previously described in SBMA patients
(19,20) and mice (21,22). In addition, we detected several hyper-
trophic fibers, as previously reported (20). Here we sought to
analyze in detail both the atrophic and hypertrophic fibers pre-
sent in SBMA muscle. Male muscle fiber size ranges between 40
and 80 lm, and the size of atrophic and hypertrophic fibers
is<40 and>80 lm, respectively (23). We measured the fiber at-
rophy and hypertrophy indexes (HIs) in the muscle of SBMA pa-
tients as described in the Material and Methods section (Fig. 1B).
As controls, we compared the muscle pathology of SBMA pa-
tients with that of patients suffering from either amyotrophic
lateral sclerosis (ALS) or other neurogenic diseases. We found
that the atrophy index (AI) was significantly (P< 0.001)
increased by>6-fold in the muscle of SBMA, ALS and neuro-
genic patients compared with control subjects. On the other
hand, the HI was significantly (P< 0.001) increased by 29-fold in
SBMA patients, whereas it was slightly and not significantly
increased by<3-fold in both ALS and neurogenic patients, indi-
cating that a high HI is a feature of the muscle pathology of
SBMA patients. Glycolytic fibers are more severely affected than
oxidative fibers in muscles composed of mixed fibers, such as
quadriceps, in knock-in SBMA mice (22). Using nicotinamide ad-
enine dinucleotide (NADH) staining, we measured the HI of oxi-
dative and glycolytic fibers in the quadriceps muscle of SBMA
patients and control subjects (Fig. 1C and D; Supplementary
Material, S2). The HI of glycolytic and oxidative fibers was
increased by 22- and 57-fold, respectively, indicating that hyper-
trophy of the oxidative fibers exceeds that of glycolytic fibers in
the muscles of SBMA patients. These results indicate that the
presence of hypertrophic fibers is a key feature of SBMA muscle,
with oxidative fibers having a higher HI compared with glyco-
lytic fibers.
Aberrant accumulation of polyglutamine-expanded AR
in the nucleus and mitochondria of SBMAmuscle
Next, we analyzed AR expression levels in the muscle of SBMA
patients and control subjects (Fig. 2A and B). AR levels were
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significantly reduced by 65% in the quadriceps muscle of SBMA
patients, despite no significant changes in the AR transcript lev-
els (Fig. 2C). We have previously shown that polyglutamine-
expanded AR is enriched in the nucleus of cultured myotubes
derived from the muscle of SBMA patients (24), and it localizes
to mitochondria (25). Therefore, we analyzed the accumulation
of AR in the cytosolic, nuclear and mitochondrial fractions of
SBMA muscle tissues and age-matched control samples. As
positive control, we verified the enrichment of the nuclear
marker, poly(ADP-ribose) polymerase (PARP), in the nuclear
fraction (Supplementary Material, Fig. S3). To assess mitochon-
drial fraction purity we verified that our mitochondrial fraction
did not contain b-tubulin and was enriched with the mitochon-
drial import receptor subunit TOM20 (Supplementary Material,
Fig. S4). Importantly, accumulation of polyglutamine-expanded
AR was decreased by 66% in the cytosolic fraction and
increased by 2-fold in the nuclear fraction compared with nor-
mal AR (Fig. 2A and B). Moreover, AR signal localized to mito-
chondria was decreased by 52% in SBMA muscles compared
with control muscles. These results indicate that accumulation
of total polyglutamine-expanded AR is decreased in the cytosol
and mitochondria, but enriched in the nucleus in the muscle of
SBMA patients.
Reduced number and altered morphology of
mitochondria in the muscles of SBMA patients
To investigate whether mitochondrial morphology and localiza-
tion was altered in the muscle of SBMA patients, we performed
transmission electron microscopy (TEM) on quadriceps femoris.
Ultrastructural examination of muscle tissues from control
individuals (Fig. 3A) and SBMA patients (Fig. 3B–F) revealed
myofibrillar disorganization and streaming in zones lacking
mitochondria (Fig. 3B) and degenerating mitochondria with ei-
ther a dense matrix (Fig. 3C and D) or dilated-hypodense matrix
(Fig. 3E) and swelling (Fig. 3F). Next, we assessed mitochondrial
abundance by molecular, biochemical and morphological ana-
lyses on SBMA and control muscles. Using real-time PCR, we
found that mitochondrial DNA (mtDNA) copy number was sig-
nificantly reduced by 40% in the muscle of SBMA patients com-
pared with control subjects (Fig. 4A). Using NADH staining, we
noticed the presence of moth-eaten fibers with oxidative en-
zyme activity progressively reduced from the periphery to the
center of the fibers, suggesting alterations in the mitochondrial
distribution and activity in SBMA oxidative fibers (Figs 1C, 4B
and C; Supplementary Material, S2). Mitochondrial mass was
also assessed by measuring the percentage of dark blue (NADH-
positive) area for field using ImageJ software (see Materials and
Methods). This analysis demonstrated a 48% reduction in mito-
chondrial amount in SBMA muscle compared with controls
(Fig. 4B and C). The activity of the mitochondrial matrix enzyme,
CS, was decreased by 35% in SBMA muscle (Fig. 4D). The enzym-
atic activity of respiratory chain complexes (OXPHOS) II, III, and
IV was also significantly decreased by 24–40% in SBMA muscle
(Fig. 4E). However, OXPHOS rates normalized to CS
(Supplementary Material, Fig. S5A), and supercomplex expres-
sion and assembly (Supplementary Material, Fig. S5B) were nor-
mal in SBMA muscle. Altogether, these ultrastructural and
biochemical analyses revealed altered mitochondrial distribu-
tion and reduced mitochondrial mass in SBMA muscle.
We then asked whether the reduction of mitochondrial
amount in SBMA muscle was associated with altered expression
Figure 1. Atrophic and hypertrophic fibers in the skeletal muscle of SBMA patients. (A) Representative images of H&E-stained cryosections of control and SBMA quadri-
ceps muscles. Scale bar, 40 mm. (B) Table showing the mean values of the atrophy and hypertrophy indexes in SBMA, ALS, and neurogenic patients and control subjects.
The values, quantified as described in Materials and Methods, are expressed as mean 6 SEM. Significance by ANOVA þ LDS Fisher post doc: atrophy index: P < 0.001
SBMA, ALS and neurogenic atrophy patients versus controls; hypertrophy index: P < 0.001 SBMA versus controls, P < 0.001 SBMA versus ALS patients, P < 0.001 SBMA
versus neurogenic patients. (C) Representative NADH-stained quadriceps muscle sections of control and SBMA subjects. Scale bar, 80lm. (D) Analysis of the hypertro-
phy index in oxidative and glycolytic fibers. Graph, mean6 SEM, n ¼ 4 SBMA patients and 5 control subjects. Significance by Student’s t test: **P < 0.01, ***P < 0.001.
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of genes involved in mitochondrial biogenesis and function,
such as peroxisome proliferator-activated receptor c coactivator
1 alpha (PGC1a, PPARGC1a) and PGC-1b (PPARGC1b), which con-
trol muscle metabolism and mitochondrial biogenesis,
mitochondrial transcription factor A (TFAM), which regulates
mitochondrial gene transcription and mitochondrial genome
replication, estrogen-related receptor a (ERRa), which regulates
the expression of nuclear genes involved in mitochondrial
Figure 2. Aberrant subcellular localization of polyglutamine-expanded AR in the muscle of SBMA patients. (A) Western blotting analysis of AR levels in total lysates,
cytosolic, nuclear and mitochondrial fractions from quadriceps muscles of SBMA patients and control subjects. b-actin, b-tubulin, PARP and ATPase were used as load-
ing controls. (B) Quantification of AR in total lysates, and nuclear, cytosolic and mitochondrial fractions. Graph, mean 6 SEM, n ¼ 7 SBMA patients and 7 control sub-
jects. Poly(ADP-ribose) polymerase (PARP), citrate synthase (CS). Significance by Student’s t test: *P < 0.05, **P < 0.01. (C) Real-time PCR analysis of the AR mRNA
transcript levels normalized to large ribosomal protein (RPLPO) mRNA in the muscle of SBMA patients and control individuals. Graph, mean 6 SEM, n ¼ 6 SBMA patients
and 3 control subjects. Significance by Student’s t test: *P < 0.05, **P < 0.01.
Figure 3. Mitochondrial abnormalities in the muscle of SBMA patients. (A) Representative image of TEM analysis of control muscle specimens. Representative images
of TEM analysis of SBMA muscle specimens. (B) TEM analysis revealed myofibrillar disorganization and Z-line streaming. (C, D) Degenerated mitochondria with dense
matrix (arrows). (E, F) Mitochondria with dilated-hypodense matrix and swelling (asterisks). Scale bar, 1 lm.
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homeostasis and biogenesis, nuclear respiratory factor 1 (NRF1),
a transcription factor that induces the expression of metabolic
nuclear genes required for mitochondrial respiration, DNA tran-
scription and replication and that has recently been linked to
SBMA pathogenesis (26), cytochrome C oxidase subunit 4
(COX4), Mn superoxide dismutase (MnSOD), a mitochondrial en-
zyme that protects mitochondria from oxidative damage, and
mitofusin 1 and 2 (MFN1 and 2), which are involved in mito-
chondrial fusion (Supplementary Material, Fig. S6). In SBMA
muscles all these genes were expressed similarly to control
muscles. These data indicated that polyglutamine-expanded AR
alters mitochondrial homeostasis without affecting the expres-
sion of genes related to mitochondrial biogenesis and function
in skeletal muscle.
Increased autophagy and mitophagy in the muscle of
SBMA patients
Reduction in the number of mitochondria can result from
increased degradation, a process known as mitophagy, which
normally occurs in cells to dispose damaged or superfluous
mitochondria through selective autophagy (27–29). Mitophagy is
a two-step process characterized by the induction of general
autophagy followed by priming of the damaged mitochondria
for mitophagic recognition and elimination (30). To determine
whether mitophagy is induced in SBMA muscle, we first asked
whether autophagy is enhanced in the muscle of SBMA pa-
tients. Ultrastructural examination of muscle tissues revealed
the presence of autophagic vacuoles in SBMA muscle (Fig. 5A).
Next, we analyzed the expression of autophagy markers, includ-
ing the lipidated form of microtubule-associated protein 1A/1B-
light chain 3 (LC3) II, which accumulates upon autophagosome
formation, sequestosome 1 (SQSTM1, p62), which accumulates
upon inhibition of autophagy flux, and Beclin-1 and lysosomal-
associated membrane protein 1 (LAMP-1), which have previ-
ously been shown to be upregulated in the muscle of SBMA
knock-in mice (22,31,32). We found that the expression levels of
LC3II, Beclin-1, and LAMP1, but not p62, were significantly
increased in the muscle of SBMA patients, indicating enhanced
autophagy (Fig. 5B). To further corroborate the autophagic
changes observed in SBMA muscle, we performed immunohis-
tochemical analysis via confocal microscopy in muscle cryosec-
tions using an antibody against LC3 to mark autophagosomes.
The LC3-positive puncta were quantified and expressed as
puncta/myofiber (Fig. 5C). The accumulation of autophagic
puncta was increased by 3-fold in SBMA muscles compared
Figure 4. Reduction of mitochondria in the muscle of SBMA patients. (A) Real-time PCR analysis of mtDNA copy number measured as the ratio between cytochrome c oxi-
dase II (COII) and nuclear amyloid precursor protein (APP) genes. Graph, mean 6 SEM, n ¼ 13 SBMA patients and 14 control subjects. (B) Mitochondrial mass expressed as
the percentage of dark blue area in NADH-stained muscle cross-sections. Graph, mean 6 SEM, n ¼ 6 SBMA patients and 5 control subjects. (C) NADH analysis of quadri-
ceps muscle of control and SBMA subjects. Scale bar, 80 lm. (D) Citrate synthase (CS) activity, expressed as nmol min1 mg1 of protein. Graph, mean 6 SEM, n ¼ 6
SBMA patients and 4 control subjects. (E) Activity of the respiratory chain complexes I–IV, expressed as nmol min1 mg1 of protein. Graph, mean 6 SEM, n ¼ 6 SBMA
patients and 4 control subjects. Significance by Student’s t test: *P < 0.05, **P < 0.01, ***P < 0.001.
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with control specimens. Notably, the LC3-positive puncta local-
ized to the center of the fiber, which corresponds to the area
with decreased NADH staining (Fig. 4C and Supplementary
Material, S2). These observations indicate that autophagy is
induced in the muscle of SBMA patients.
Next, we assessed whether mitophagy is enhanced in the
muscle of SBMA patients. To address this question, we isolated
the mitochondrial fraction from SBMA and control muscles. We
then analyzed the mitochondrial enrichment of proteins that
prime damaged mitochondria and allow the recruitment of the
autophagosome for mitophagy, such as BCL2/Adenovirus E1B
19kDa Interacting Protein 3 (BNIP3), PTEN-induced putative kin-
ase 1 (PINK1), and the E3 ubiquitin-protein ligase parkin (PARK2)
(29,33,34). BNIP3 and PINK1, but not PARK2, were increased by
3- and 4-fold, respectively, in isolated SBMA muscle mitochon-
dria compared with controls (Fig. 6A). To test whether other E3
ubiquin ligases involved in mitophagy, such as MUL1 (35) and
Gp78 (36), are induced in SBMA muscle, we measured the tra-
script levels of these factors by real-time PCR (Supplementary
Material, Fig. S7). However, we did not find any increase in the
expression of these genes in SBMA muscles compared with con-
trol specimens. Mitochondria degraded through mitophagy are
polyubiquitinated (37). The amount of ubiquitinated proteins
was augmented in the mitochondria isolated from SBMA
muscles (Fig. 6B). By confocal microscopy analysis of quadriceps
muscle cryosections, we found that the LC3-positive puncta
colocalized with ATPase-positive-mitochondria, and double-
positive vesicles were increased by 4.5-fold in SBMA muscle
(Fig. 7A and B). Interestingly, we noticed that some SBMA
muscle fibers had central regions rich in autophagic vacuoles
(LC3-positive), but devoid of mitochondria, suggesting a mito-
phagic process that leads to removal of mitochondria. These
areas overlapped with the NADH-negative central area of oxida-
tive fibers (Fig. 4C; Supplementary Material, Fig. S2) and the
myofibrillar disorganization and streaming in zones lacking
mitochondria observed by TEM (Fig. 3B). Selective mitophagy is
also controlled by mitochondrial dynamics (37). Mitochondrial
fission facilitates mitophagy and is operated by specific
mitochondria-associated proteins, such as dynamin-related
protein 1 (Drp1) and mitochondrial fission 1 protein (hFis1)
(27,38). Both Drp1 and hFis1 were significantly increased by 1.6-
and 1.7-fold, respectively, in SBMA mitochondria, suggesting
augmented fission events, in line with increased mitophagy
(Fig. 7C). Taken together, these observations show that mitoph-
agy is induced in the muscle of SBMA patients.
Lipid composition of mitochondria is altered in the
muscle of SBMA patients
Mitophagy can result from defects in membrane lipid biosyn-
thetic pathways (39). We have recently shown that muscles,
such as quadriceps, are characterized by major lipid alterations
in SBMA knock-in mice (22). To determine whether the lipid
composition of mitochondria in the muscle of SBMA patients is
altered, we performed untargeted lipidomic analysis by mass
spectrometry on mitochondria isolated from the quadriceps
muscles of SBMA patients and control subjects (Fig. 8A).
In SBMA mitochondria, the peculiar structural phospholipid of
the inner mitochondrial membrane (IMM), cardiolipin (CL), was
decreased by 52%, whereas the levels of phosphatidylethanol-
amine (PE) and PE-precursor-phosphatidylserine (PS) were
increased by 1.5- and 2-fold, respectively, compared with con-
trol muscles. To function optimally, immature CL must have its
fatty acids remodeled into a mature form (40). We found that
97% of total CL species are represented by molecules having
acyl moieties combinations between 3(C18:2)/1(C18:3) and
1(C18:2)/3(C18:1), including tetralinoleoyl cardiolipin (4(C18:2))
which alone accounts for 50% of the total CL (Fig. 8B).
Figure 5. Increased autophagy in the muscle of SBMA patients. (A) TEM analysis of quadriceps muscle biopsies derived from two SBMA patients revealed the presence
of autophagic vacuoles (AV). Scale bar, 1 lm. (B) Western blotting analysis of LC3-II, p62, Beclin-1 and LAMP1 levels. b-actin was used as loading control. Graph, mean 6
SEM, n ¼ 10 SBMA patients and 5 control subjects (top panels), and 9 SBMA patients and 9 control subjects (bottom panel). (C) Immunofluorescence analysis of LC3
in control and SBMA muscle tissues. The number of autophagosomes/fiber was measured as the number of green object-for-fiber (puncta/fiber). Graph, mean 6 SEM,
n ¼ 50 fibers from each muscle sample derived from 11 SBMA patients and 10 control subjects. LC3 was detected using a specific antibody. Scale bar, 20lm. Significance
by Student’s t test: *P < 0.05, **P < 0.01, ***P < 0.001.
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In mammals, tetralinoleoyl CL is the most abundant molecular
species of CL in highly oxidative tissues, such as skeletal muscle
(41). In SBMA muscle mitochondria the ratio between the single
CL molecular species to total CL was similar to control, indicat-
ing a homogeneous reduction of all the CL molecular species
(Fig. 8B). These data suggested defects in synthesis rather than
processing of CL to the mature forms. CL is synthesized by car-
diolipin synthase (CRLS1), a key enzyme involved in the de novo
biosynthesis of immature CL (40). We hypothesized that the
decreased synthesis in cardiolipin was owing to reduced ex-
pression of CRLS1. By real-time PCR, we found that the tran-
script levels of CRLS1 were decreased by 51% in SBMA muscles
compared with control muscles (Fig. 8C). In conclusion, these
observations show major morphological and biochemical mito-
chondrial alterations in the muscle of SBMA patients associated
with reduced CL synthesis. Because CL plays a critical role in
mitochondrial homeostasis (Fig. 9), our results suggest a causa-
tive link between alterations in CL levels, mitochondrial dys-
function and muscle atrophy in SBMA.
Discussion
Analysis of muscle biopsy specimens revealed that SBMA pa-
tients have both neurogenic atrophy and myopathic changes, as
previously reported (2,19,20). In addition, SBMA muscle was
characterized by the presence of hypertrophic fibers, which are
not often detected in the muscle of patients suffering from ALS
and denervative diseases, indicating that the presence of a large
number of hypertrophic fibers is a feature of SBMA skeletal
muscle pathology. Hypertrophic fibers can be detected also at
late stage of disease in mice overexpressing polyglutamine-
expanded AR (21). On the other hand, such hypertrophic fibers
are absent in the muscles of knock-in SBMA mice (22).
Interestingly, the size of oxidative hypertrophic fibers was big-
ger than that of glycolytic fibers, indicating that the hypertrophy
of the oxidative fibers exceeds that of glycolytic fibers. We have
previously shown that in SBMA patients and knock-in mice
muscles composed of both glycolytic and oxidative fibers
undergo a metabolic switch toward oxidative phosphorylation
(22). Moreover, glycolytic fibers were more severely affected
than oxidative fibers, and this was associated with impaired
glycolysis (22). It is possible that glycolytic fibers are particularly
sensitive in SBMA, and that a compensatory mechanism leads
to hypertrophy of oxidative fibers.
Expression of polyglutamine-expanded AR in muscle is key
to neurodegeneration (16,17,21). Here, we analyzed for the first
time polyglutamine-expanded AR accumulation and subcellular
localization in the intact muscle of SBMA patients. We found a
significant reduction of polyglutamine-expanded AR in total lys-
ates of SBMA muscles compared with control muscles. This re-
duction in mutant AR accumulation was not associated with
reduced AR gene transcription, suggesting additional mechan-
isms responsible for reduced AR accumulation, such as
increased degradation. Polyglutamine-expanded AR is mainly
Figure 6. Mitophagy is induced in the muscle of SBMA patients. (A, B) Western blotting analysis of BNIP3, PINK1, PARK2 and ubiquitin levels in mitochondria isolated
from the quadriceps muscle of SBMA patients and controls subjects normalized to CS activity. TOM20 and ATPase were used as loading controls. Graph, mean 6 SEM,
n ¼ 5 SBMA patients and 5 control subjects. Significance by Student’s t test: *P < 0.05.
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degraded by the ubiquitin proteasome system and autophagic
processes (11,42–46). Basal autophagy is increased in animal
models of SBMA (22,31,32), and in the muscle of SBMA patients,
as shown here. These data suggest that activation of the auto-
phagic/lysosomal pathway may result in increased AR turnover
and could be a tissue-specific protective strategy to cope with
the expression of mutant AR. Despite the levels of total AR being
decreased in SBMA muscle, its accumulation in the nuclear frac-
tion was increased compared with control specimens. Nuclear
localization of polyglutamine-expanded proteins plays a critical
role in the neurodegenerative process. Huntingtin predomin-
antly localizes to the cytosol, but it translocates to the nucleus
upon polyglutamine expansion (47). Moreover, deposition of
polyglutamine-expanded proteins in forms of nuclear inclu-
sions has been observed in SBMA, as well as HD, DRPLA and
several types of SCAs (48). Importantly, nuclear localization of
proteins linked to polyglutamine diseases is a prerequisite to
toxicity (10,42,49–51). Consistent with these observations, accu-
mulation of polyglutamine-expanded AR was increased in the
nucleus of differentiated SBMA myotubes, but not in proliferat-
ing SBMA myoblasts, suggesting that the process of muscle
differentiation is associated with an abnormal nuclear accumu-
lation of the disease protein (24). AR nuclear translocation
occurs upon androgen binding and is mediated by importin-a
and b, which move the cargo import complex through the nu-
clear pore complex into the nucleus (52). Abnormalities in the
nuclear pore complex have recently been described in ALS
(53,54), and these defects may contribute to the abnormal sub-
cellular localization of specific proteins linked to motor neuron
diseases, such as fused in sarcoma (FUS), TAR DNA-binding pro-
tein 43 (TDP-43) and AR. Further analysis is required to address
why polyglutamine-expanded AR accumulates in the nucleus,
whether it results from increased transport to or reduced export
from the nucleus, and whether the nuclear pore complex is dys-
functional in SBMA muscle. Another important aspect conse-
quent to the aberrant nuclear accumulation of polyglutamine-
expanded AR is that nuclear AR works as a transcription factor
activated by androgens. Several genes regulated by AR and
whose expression is altered in SBMA muscle code for mitochon-
drial proteins (22,55), raising the possibility that an increased
accumulation of mutant AR in the nucleus may cause mito-
chondrial abnormalities by altering the expression of nuclear
genes encoding mitochondrial proteins.
Expression of polyglutamine-expanded AR alters mitochon-
drial homeostasis (reviewed by 56). Mitochondrial abnormal-
ities, including reduced number, mass and membrane
Figure 7. Increased mitophagy and mitochondrial fission proteins in the muscle of SBMA patients. (A) Representative images of anti-LC3 (green) and anti-ATPase (red)
immunostaining of control and SBMA muscle tissues. Zoom: magnification of the marked area (circle). Scale bar, 20lm. (B) Number of colocalized autophagosome-
mitochondria (yellow puncta), measured as number of yellow puncta/fiber. Graph, mean 6 SEM, n ¼ 11 SBMA patients and 10 control subjects, n of fibers: 50 for each
sample. (C) Western blotting analysis of Drp1 and hFis1 levels normalized to CS activity in mitochondria isolated from the quadriceps muscle of SBMA patients
and control subjects. ATPase was used as loading control. Graph, mean 6 SEM, n ¼ 4 SBMA patients and 4 control subjects. Significance by Student’s t test: *P < 0.05,
**P < 0.01.
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potential, were previously reported in cell and animal models
of SBMA (22,25). However, a detailed characterization of mito-
chondria in intact muscle tissues derived from SBMA patients
was still missing. Here, we describe for the first time mito-
chondrial abnormalities detected in muscle biopsy specimens
derived from SBMA patients. We found reduced number and
altered morphology and distribution of mitochondria in
SBMA muscle. Polyglutamine-expanded AR may alter mito-
chondrial homeostasis through an indirect effect, by modify-
ing the expression of nuclear genes encoding mitochondrial
proteins, such as genes involved in glycolysis (22,55). On the
other hand, polyglutamine-expanded AR may alter mitochon-
drial homeostasis and function through a direct effect.
Indeed, polyglutamine-expanded AR has been detected in the
mitochondrial fraction in motor neuron-derived cells (25),
myoblast cells (57) and quadriceps muscle of SBMA patients,
as reported here. Interestingly, normal and polyglutamine-
expanded AR have been shown to interact with COXVb (58).
Polyglutamine-expanded AR may affect mtDNA. Multiple
mtDNA deletions were detected in a SBMA patient (59), and
mtDNA was reported to be decreased in leucocytes derived
from SBMA patients, which negatively correlated with the
length of the AR pathogenic polyglutamine tract (60).
However, mtDNA was also decreased in female carriers,
which are usually non-symptomatic. Here, we report for the
first time that mtDNA is decreased in the muscle of SBMA pa-
tients. Possibly, this decrease reflects the reduction in the
number of mitochondria observed in the muscle of SBMA pa-
tients, which is consistent with previous observations in cell
models of SBMA (25).
Emerging evidence indicates that autophagy is aberrant in
SBMA with tissue-specific changes in autophagy flux and acti-
vation. Autophagy flux is blocked in the motor neurons of mice
overexpressing polyglutamine-expanded AR (61). On the other
hand, autophagy is induced specifically in the muscle of SBMA
knock-in and transgenic mice (22,32,61), and SBMA patients, as
shown here. The observations that reduced autophagic activity
by either Beclin-1 haploinsufficiency or a high-fat diet in SBMA
knock-in mice increased skeletal muscle fiber size and signifi-
cantly extended lifespan suggest that excessive autophagy acti-
vation in SBMA muscle is detrimental (22,46). Extending these
findings, we describe for the first time to our knowledge that a
selective type of autophagy, namely mitophagy, is induced in
SBMA muscle. Mitophagy specifically removes mitochondria, a
process that occurs even under nutrient-rich conditions and
that is mechanistically distinct from basal autophagy (29,38).
Mitophagy leads to clearance of damaged mitochondria. In this
model, fission events produce two functionally distinct mito-
chondria, one with high mitochondrial membrane potential
(DWm), and the other with reduced DWm. The depolarized mito-
chondria are eliminated by mitophagy (62). The overall process
is also controlled by mitochondrial dynamics, as it is associated
with mitochondrial fragmentation (63). Consistent with this no-
tion, we found augmented expression of fission proteins, such
as Drp1 and hFis1, in mitochondria isolated from SBMA muscle,
indicating increased mitochondrial fragmentation, a mechan-
ism to segregate dysfunctional or damaged components of the
mitochondrial network. Mitophagy is mainly mediated by two
pathways, the PINK1/PARK2 and BNIP3/NIX systems (64). In the
PINK1–PARK2 pathway mitophagy is usually triggered by an ac-
cumulation of PINK1 on the outer mitochondrial membrane
(OMM) of dysfunctional mitochondria, where it phosphorylates
and activates the E3 ubiquitin ligase PARK2 (37,38). PARK2 then
ubiquitinates mitochondrial proteins of the OMM, leading to re-
cruitment of autophagy receptors, such as p62, which recognize
the ubiquitinated mitochondria and recruit them to the
Figure 8. Reduced cardiolipin levels and biosynthesis in the muscle of SBMA patients. (A) Mass spectrometry lipidomic analysis of mitochondrial membranes isolated
from SBMA patients and control subjects. Cardiolipin (CL), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylcholine (PC) and phosphatidylinositol
(PI) amounts were normalized to CS activity. Graph, mean 6 SEM, n ¼ 4 SBMA patients and 4 control subjects. (B) Composition of CL molecular species in control and
SBMA muscle samples. The values are expressed as mean 6 SEM of two independent experiments. #Percentage of the molecular species/total CL. *Range of the major
combinations among the shown acyl moieties. (C) Real-time PCR analysis of cardiolipin synthase (CRLS1) normalized to RPLPO in the muscle of SBMA patients and control
subjects. Graph, mean 6 SEM, n¼5 SBMA patients and 6 control subjects. Significance by Student’s t test: *P < 0.05, **P < 0.01.
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autophagosome by binding to the lipidated form of LC3.
Recently, an alternative pathway for PINK1-mediated mitoph-
agy has been described, which is independent of p62. PINK1 has
been shown to directly recruit the autophagy receptors, NDP52
and optineurin, to induce mitophagy in a process that is ampli-
fied by PARK2 (65). We found increased association of PINK1
with enhanced ubiquitination of mitochondria isolated from
SBMA muscles, indicating that mitophagy is activated in the
muscle of SBMA patients. However, we did not observe
enhanced recruitment of PARK2 to SBMA mitochondria. Other
E3 ubiquitin ligases may regulate mitophagy in SBMA muscle.
MUL1 (35) and Gp78 (36) have been described as distinct cellular
E3 ubiquitin ligases that eliminate damaged mitochondria, act-
ing in parallel to the PINK1–PARK2 pathway. Although the ex-
pression of MUL1 and Gp78 did not change in SBMA muscles
compared with control specimens, it is possible that these E3
ubiquin ligases play a role in mitophagy in SBMA muscle.
Alternatively, PINK1 can exert functions on SBMA mitochondria
other than mediating mitophagy. Further studies are required
to clarify the mechanism leading to PINK1 enrichment on SBMA
mitochondria and to establish which E3 ubiquitin ligases are re-
sponsible for increased mitophagy in SBMA muscle. The BNIP3/
NIX system works by directly binding LC3 and docking the nas-
cent autophagosome to the mitochondria with enriched BNIP3
or NIX (64). In muscle, mitochondrial priming is mediated
prevalently by the mitophagic protein BNIP3, and to a minor ex-
tent by the PINK1–PARK2 signaling pathway (66). Additionally,
BNIP3 recruitment, mediated by forkhead box O transcription
factors (FOXO), is sufficient to induce mitophagy (67,68). As
observed in the present study, SBMA muscle mitochondria had
3-fold-increase in the levels of BNIP3, supporting a role for this
mitophagy pathway in SBMA muscle.
Figure 9. Cartoon representing cardiolipin functions in mitochondria. (A) Cardiolipin (CL) is essential for normal electron transport and proton translocation activity of
complex I, III and IV and, with its negative charged head group, CL attracts and provides a local pool of protons necessary for complex V function. CL also promotes the
assembling of OXPHOS complexes into supercomplexes, which implies an improvement of electron transfer and a reduction in ROS production. (B) CL is involved in
mitochondrial dynamics. It is critical for the fusion of the IMMs via its interaction with optic atrophy (Opa1), promoting its dimerization and enhancing its GTPase ac-
tivity. CL also has a role in the fission pathway. After its transfer from the IMM to the OMM, it mediates Drp1 recruitment to mitochondrial membrane surface and en-
hances Drp1 GTPase activity. (C) In concert with complex V, CL promotes cristae formation. CL structure composed of two phosphatidyl moieties with a single glycerol
group promotes negative curvature of membrane. (D) CL externalization from IMM to OMM acts as an ‘eat-me-signal’ for the autophagic machinery, promoting
mitophagy. The negative charged head group of externalized CL interacts with the basic CL binding sites of LC3, which mediates both autophagosome formation and
cargo recognition. LC3 recognizes CL more effectively than its metabolites and oxidized CL, suggesting that CL oxidation is not a prerequisite for mitochondria elimin-
ation through mitophagy. (E) CL plays a role in apoptosis. During apoptosis initiation, CL undergoes peroxidation catalyzed by cytochrome c. Mitochondrial injuries
generate ROS, which cause a significant amount of CL to flip to the outer leaflet of IMM, where it binds to cytochrome c. After peroxidation and externalization, CL
binds a set of apoptotic proteins such as caspase-8, which are recruited to the mitochondrial surface. Caspase-8 cleaves Bid to a truncated form (tBid), which induces
Bax/Bak oligometization thereby permeabilizing the membrane and releasing cytochrome c. AV, autophagic vacuole; cyt c, cytochrome c; IMS, intermembrane space;
IMM, inner mitochondrial membrane; OMM, outer mitochondrial membrane.
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Here, we show that autophagy and mitophagy are activated
in SBMA muscle, supporting the idea that mitochondrial dysfunc-
tion and mitophagy activation are key processes occurring in the
muscle of SBMA patients. Mitophagy has been involved in several
neurodegenerative diseases, such as Parkinson’s disease and
Alzheimer’s disease. Moreover, mitophagy has recently been
shown to occur in neuroblastoma cells expressing ALS-linked
mutant TDP-43 (69). Pathological conditions associated with the
loss of muscle mass and force are often characterized by alter-
ations in the mitochondrial network, function and mitophagy
(37). Optineurin and valosin-containing protein are necessary for
mitochondrial clearance in response to depolarization, a function
that is disrupted by mutations that cause ALS and multisystem
proteinopathy (70,71). Mitochondrial dysfunction and autophagy
defects are detected in diseases with a primary muscle compo-
nent, such as Ullrich congenital muscular dystrophy, Bethlem
myopathy and congenital myosclerosis, which are caused by mu-
tations in the genes encoding the extracellular matrix protein col-
lagen VI (72). Congenital muscular dystrophy with mitochondrial
structural abnormalities (CMDmt) is caused by loss of function
mutations in the gene coding for choline kinase b, a key enzyme
in the de novo synthesis of phosphatidylcholine (PC).This is char-
acterized by the presence of enlarged mitochondria that localize
at the periphery of muscle fibers, with central areas devoid of
mitochondria (39,73). Muscles of either CMDmt patients, or mice
carrying loss of function mutations of choline kinase b, show
decreased levels of PC, increased ROS production, decreased
complex III activity, increased mitochondrial polyubiquitination
and association of PINK1/Parkin, p62, LC3, and decreased mtDNA,
suggesting increased mitophagy. Importantly, several of these
abnormalities were also present in SBMA muscle. Therefore,
maintenance of a functional mitochondrial network is particu-
larly important for skeletal muscle, a post-mitotic tissue that
cannot dilute damaged or dysfunctional mitochondria through
cellular division, but that is yet able to activate the mitochondria
quality control pathway. In physiological conditions, muscle has
a highly interconnected mitochondrial network and the entire
mitochondrial compartment works as a single dynamic unit to
maximize ATP synthesis, which is necessary to support the high
ATP demand during contraction (74). Indeed, a highly fused mito-
chondrial network is important for proper mitochondrial calcium
buffering and for the optimal production of ATP, with a higher
cristae density and an ideal organization of electron transfer
chain components in supercomplexes (75,76). Mitochondrial fu-
sion is advantageous under conditions of high energy demand
and optimizes mitochondrial function in stress conditions, as fre-
quently occurs in skeletal muscle (76). Under stress conditions,
such as upon expression of polyglutamine-expanded AR, dys-
functional mitochondria are separated from the mitochondrial
network and removed via mitophagy, and the occurrence of nor-
mal mitochondrial biogenesis may not be sufficient to compen-
sate for this increase in mitochondrial disposal. The question
remains as to whether mitophagy is an adaptive process to re-
move dysfunctional mitochondria and reduce muscle damage, or
maladaptive, leading to excessive mitochondrial clearance and
unbalanced bioenergetics.
The muscle phenotype of SBMA and CMDmt patients sug-
gests that alterations of the biosynthetic pathways of phospho-
lipids in mitochondria are critical for mitochondrial and
skeletal muscle homeostasis and may lead to mitophagy.
Mitochondrial membranes have a very well defined lipid com-
position, with a high content of phospholipids and a low con-
tent of sterols and sphingolipids. Most of the mitochondrial
lipids are synthesized in the endoplasmic reticulum and then
transported to the mitochondria, where they are redistributed
between the outer and IMMs. An exception is represented by
the diglycerophospholipid CL, which is synthesized in mito-
chondria from endoplasmic reticulum-derived phosphatidic
acid, and is then enriched in the IMM (77). Among phospho-
lipids CL has a peculiar and unique structure composed of two
phosphatidyl residues linked by a glycerol moiety (78). CL is
involved in numerous distinct mitochondrial activities, it plays
important roles in mitochondrial functions, and maintenance
of normal CL levels is key to mitochondrial function and stabil-
ity (Fig. 9). CL controls mitochondrial cristae architecture and
the stabilization of physical properties of mitochondrial mem-
branes, and it regulates the stability and function of mitochon-
drial proteins, including the electron transport chain complexes
(79,80). CL binds to and optimizes the activity of complexes III,
IV and V, and it regulates mitochondrial dynamics, protein im-
port and apoptosis. Loss of CL decreases the stability and func-
tion of complexes III and IV (81), and it results in mitochondrial
depolarization and altered mitochondrial function (82). CL also
participates in the structural organization and stabilization of
the respiratory chain complexes into supercomplexes (83–85).
Moreover, redistribution of CL to the OMM has been shown to
serve as a signal for mitophagy (86). Cytochrome c-catalyzed
peroxidation of CL and its externalization occurs during apop-
tosis initiation (80). Thereafter, CL translocates to the outer leaf-
let of the OMM, where it interacts with and activates several
apoptotic proteins (87). In SBMA muscle, we found decreased
levels of all the different CL species. The decrease in CL levels
were coupled with increased levels of PE and PS. PE has previ-
ously been shown to compensate for some defects concerning
mitochondrial morphology owing to the loss of CL in yeast (88).
However, CL and PE have distinct effects on the stability and as-
sembly of respiratory complexes, and therefore the increase in
PE levels may not be sufficient to compensate for the loss of CL
in SBMA muscle (89). Moreover, alterations in CL abundance are
associated with pathological states, including aging (90) and
diabetes (91). SBMA is an age-related disease often associated
with diabetes. Our observations link altered mitochondrial lipid
metabolism, perturbation of CL levels, and mitochondrial dys-
function to skeletal muscle atrophy in SBMA. Further investiga-
tion is needed to establish whether there is a causative link
between muscle hypertrophy, mitochondrial abnormalities,
mitophagy and CL loss in SBMA muscle.
In eukaryotic mitochondria, CL is synthesized by CRLS1, a
key enzyme involved in the biosynthesis of immature CL. It
catalyzes the irreversible condensation reaction in which the
phosphatidyl group of cytidine diphosphate diacylglycerol
(CDP-DAG) is linked to phosphatidylglycerol (PG) (77). After bio-
synthesis, immature CL undergoes deacylation and remodeling,
to generate the different molecular species with diverse fatty
acid composition. In SBMA muscle, CRLS1 expression was
decreased by 52%, which may explain why CL is reduced. CRLS1
is regulated by androgens (92,93), raising the possibility that AR
directly regulates its expression. In models of chronic denerv-
ation, CL levels are decreased in muscle (94,95) in association
with an upregulation of both biosynthesis enzymes CRLS1 and
CTP:PA-cytidylyltransferase-1 (95). This compensatory response
during chronic muscle denervation differs from our results of
CRLS1 downregulation in SBMA muscle. It is possible that, in
addition to the effect of denervation, the underlying mechan-
isms of CL reduction in SBMA muscle may be caused by altered
androgen signaling and AR function. The unbalanced
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phospholipid membrane composition of SBMA mitochondria
may induce increased fragility, and it may lower the stress
threshold. SBMA mitochondria may be more sensitive to the
normal increase in ROS production that occurs during normal
skeletal muscle activity, causing transient physiological oxida-
tive stress (37). SBMA muscle mitochondria have an altered
membrane lipid composition, which may cause a latent fragility
and explain the mitochondriapenia as a result of an imbalance
in mitochondrial turnover that favors mitochondrial removal.
In conclusion, we show here for the first time that mitochon-
drial mass is reduced, mitochondrial morphology and lipid
composition is aberrant, and mitophagy is enhanced in the
muscle of SBMA patients. These observations have been ob-
tained in muscle biopsy specimens derived from SBMA patients
with various degrees of motor impairment and/or disease dur-
ation, ranging from a mild to severe phenotype. We propose a
model whereby abnormal mitochondria are subjected to quality
control and eliminated, leading to aberrant mitochondrial net-
work and function in SBMA muscle. These findings highlight
the relevance of mitochondria in disease pathogenesis and
identify mitochondrial homeostasis as a target for therapeutic
manipulation.
Materials and Methods
Human samples
Anonymized control and patient biopsy sample collection was
approved by the local Ethics Committee. Written informed con-
sent was obtained from each patient. In all cases, biopsied
muscles were clinically affected and showed weakness and/or
atrophy. Myopathic changes together with neurogenic atrophy
were observed in all muscle biopsies. We studied 19 SBMA pa-
tients followed at our Neuromuscular Clinic of the University of
Padova (Supplementary Material, Table S1). Main clinical data,
including age at disease onset, age at biopsy and first clinical
symptoms were recorded for each patient. Genomic DNA was
extracted from the peripheral blood according to standard pro-
cedures. CAG repeats fragment sizing in AR gene was performed
on an ABI PRISM 3700 DNA Sequencer (Applied Biosystems,
Foster City, CA, USA). The specific length of CAG repeats was
further verified via Sanger sequencing. Muscle biopsies were ob-
tained using an open biopsy procedure with the collection of
100–200 mg of muscle tissue. All biopsies were immediately fro-
zen in liquid nitrogen for histopathology and biochemical ana-
lyses and stored at 80 C until analyzed. Muscle biopsies from
18 age- and sex-matched healthy subjects, with no signs of
neuromuscular diseases and with normal creatine kinase levels
were used as controls. Muscle biopsies from 5 age-matched fe-
male controls and 46 age-matched male patients affected with
neurogenic diseases, including ALS (32) and sensory-motor neu-
ropathies (14), followed at our Neuromuscular Clinic of the
University of Padova, were used for atrophy and HIs evaluation.
Nuclear/cytosolic and mitochondria fractionation
Nuclear and cytosolic fractions were obtained by treating 50 
20 lm thick fresh-frozen sections of muscle biopsies with the
NE—PER Nuclear and Cytoplasmic Extraction kit (Thermo
Scientific), supplemented with protease inhibitors cocktail
(Sigma). Protein concentration was determined by BCA assay
(Thermo Scientific). For each sample, 30 lg of nuclear and cyto-
solic proteins were loaded for the different analyses. Nuclear
enrichment was tested by western blotting as the ratio between
PARP (nuclear marker) and b-tubulin (cytosolic marker) in total
lysate, nuclear and cytosolic fractions of each muscle sample.
As shown in Supplementary Material, Figure S3, in total lysate
and the cytosolic fraction the PARP:b-tubulin ratio was 0.0760.
01 and 0.2160.14, respectively, whereas in the nuclear fraction
this ratio was 6.0360.70. This procedure yielded a 29- and 86-
fold enrichment of the nuclear fraction when compared with
cytosolic fraction and the total homogenate, respectively.
Human muscle mitochondria were isolated from frozen
muscle specimens (50–100 mg), as previously described (96).
Each muscle sample was diluted 1:10 in Buffer A (20 mM HEPES,
100 mMKCl, 1 mM EDTA, 2 mM b-mercaptoethanol, 0.3% BSA),
homogenized using a glass pestle in a glass potter and centri-
fuged at 800g for 10 min at 4 C. The resulting supernatant (S1)
was transferred to a new tube and the pellet was diluted 1:20 in
Buffer A and centrifuged at 800g for 10 min at 4 C, to increase
the yield of mitochondria. The resulting supernatants (S1þS2)
were pooled and centrifuged at 10 000g for 10 min at 4 C.
Following this centrifugation step, supernatant was discarded
and the pellets containing the mitochondria were suspended in
the isotonic MSEM buffer (3 ml/initial g of tissue, 220 mM
Mannitol, 70 mM sucrose, 1 mM EDTA, 2 mM b-mercaptoetha-
nol, 5 mM MOPS), aliquoted in several tubes, centrifuged at
20 000g for 10 min at 4 C and stored at 80 C until further ana-
lysis. Mitochondrial enrichment was tested by western
blotting as the ratio between TOM20 (mitochondrial marker)
and b-tubulin (cytosolic marker) in the total lysate and in the
isolated mitochondria of muscle from two SBMA and two con-
trol subjects. As shown in Supplementary Material, Figure S4,
the total lysate TOM20:b-tubulin ratio was 0.5060.06, whereas
in isolated mitochondria it was 7.8561.36. This procedure
yielded a 16-fold enrichment of the mitochondrial fraction com-
pared with the total homogenate.
Molecular analyses
To measure mtDNA copy number, total DNA was isolated from
muscle tissue using the DNeasy Blood & Tissue Kit (Qiagen).
Quantitative polymerase chain reaction was performed using a
ABI PRISM 7000 light cycler, using Platinum quantitative PCR
SuperMix-UDG with ROX (Invitrogen). The mtDNA copy number
was estimated as previously described (97). Briefly, the mitochon-
drial encoded gene, cytochrome c oxidase (COII), was amplified
and compared with the amplification profile of the nuclear single
copy gene, amyloid precursor protein (APP). The relative level for
each gene was calculated using the ‘1=2ˆCt method’. In all experi-
ments, each sample was analyzed in triplicate. Probes were
labeled with FAM and TAMRA. For mRNA quantification, total
RNA was isolated from muscle biopsies using TRIzol Reagent
(Life Technologies). First-Strand cDNA synthesis was performed
using High-Capacity cDNA Reverse Transcription Kit (Life
Technologies) and transcript levels were quantified by SYBER
Green Real-Time PCR (Life Technologies) using the ABI PRISM
7000 sequence detection system. Primer sequences are listed in
Supplementary Material, Table S2.
Biochemical analyses
For western blotting analysis, total muscle lysates were ob-
tained by cutting 30  20 lm-thick fresh-frozen sections from
each muscle biopsy and placing these sections on ice for 30 min
in 200 ll of RIPA buffer (65 mM Tris, 150 mM NaCl, 1% NP-40,
0.25% Na-DOC, 1 mM EDTA, pH 7.4) that contained 2 ll of a
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protease inhibitor cocktail (Sigma) (24). After centrifugation at
20 000g for 20 min at 4 C, the supernatant was collected and
stored at –80 C until use. Protein concentration was determined
by BCA assay (Thermo Scientific). Thirty mg of protein from each
sample were loaded for the different analyses. The protein sam-
ples were separated by SDS-PAGE (7.5 or 10% polyacrylamide
gels) and transferred to a nitrocellulose membrane (Whatman).
Membranes were blocked in 5% (w/v) fat-free milk in 0.02 M
Tris/HCl pH 7.5, 137mM NaCl, and 0.1% (v/v) Tween-20 for 1 h at
room temperature and then incubated overnight at 4 C with
the primary antibodies diluted in blocking solution. Bound anti-
body was visualized using an ECL reagent (GE Healthcare).
Integrated optical density of each band was calculated with
commercial software (Gel-Pro Analyzer 3). The primary antibod-
ies used were: anti-AR polyclonal (Santa Cruz, N-20, sc-816,
1:1000); anti-ACTB monoclonal (Chemicon International,
MAB1501, 1:20 000); anti-PARP-1 polyclonal (Santa Cruz, H-250,
1:2000); anti-b-tubulin polyclonal (Santa Cruz, H-235, 1:1000);
anti-TOM20 polyclonal (Santa Cruz, Sc-11415, 1:1000); anti-
SQSTM1/p62 monoclonal (Sigma, 041M4812 1:2000); anti-LC3
monoclonal (Sigma, L7543, 1:1000); anti-Beclin-1 polyclonal (Cell
Signaling, 3738, 1:1000); anti-LAMP-1 monoclonal (DSHB, H4A3,
1:400); anti-BNIP3 polyclonal (Sigma, B7931, 1:1000); anti-PINK1
monoclonal (Cell Signaling, D8G3, 1:1000); anti-PARK2 monoclo-
nal (Santa Cruz, Sc-32282, 1:1000); anti-Ubiquitin monoclonal
(Millipore, MAB1510, 1:1000); anti-DLP1 monoclonal (BD
Biosciences, 611112, 1:1000); anti-Fis1 polyclonal (Alexis, ALX-
210-907, 1:1000); anti-ATPase polyclonal (home-made), generous
gift of Prof. F. Dabbeni-Sala from University of Padua.
For Blue Native PAGE (BN-PAGE), mitochondrial pellets were
resuspended at 10 mg/ml in Native Buffer (Invitrogen) with 4%
Digitonin (Sigma) for 1 h on ice and centrifuged 20 min at
16 000g at 4 C. The supernatant was collected and 1% G250
sample buffer additive (Invitrogen) was added. Ten micrograms
of mitochondrial membrane proteins were loaded onto a 3–12%
BisTris gel (NativePAGETM NovexVR Bis-Tris Gel System,
Invitrogen), as manufacturers’ instructions, and transferred to
Immobilon-P transfer membrane (Millipore). Membranes were
blocked in 2% bovine serum albumin in 0.02 M Tris/HCl pH 7.5, 137
mM NaCl, and 0.1% (v/v) Tween-20 for 1 h at room temperature
and then incubated for 1 h at room temperature with the primary
antibodies diluted in blocking solution. Visualization of the anti-
body protein complexes was achieved by using enhanced chemi-
luminescence (LiteAblot-Turbo, Euroclone) and the ChemiDocTM
XRSþSystem (Bio-Rad). Densitometry was performed with the
Gel-Pro Analyzer 3 software. The primary antibodies used were:
anti-MTCO1 monoclonal (Abcam, ab14705, 1:5000), anti-Complex I
subunit NDUFB8 monoclonal (Molecular Probes, 459210, 1:5000)
and anti-GRP75 polyclonal (Santa Cruz, sc-13967, 1:5000).
OXPHOS activities were tested as previously described (98).
Briefly, muscle biopsies (20–30 mg) were homogenized in
Sucrose buffer 250 mM (0.121 g Tris, 0.15 g KCl and 0.038 g EGTA
in a final volume of 50 ml). On the same day of the experiment,
0.854 g of sucrose was added to 10 ml of this buffer, and then the
homogenate was centrifuged at 600g for 10 min at 4 C. The
supernatant was transferred into a new tube on ice for respira-
tory chain complex analysis. CS was quantified as previously
described (98). A protein amount corresponding to a CS activity
of 2500, 4000 or 5000 nmol min1 mg1 was loaded for the differ-
ent analyses. Protein concentration was determined by
Bradford assay (Sigma). The enzymatic activities of respiratory
chain complexes I–IV were assayed in duplicate or triplicate with
a single-wavelength, temperature-controlled spectrophotometer
at 37 C, as previously described (98). The enzymatic activities for
each mitochondrial enzyme was calculated as nmol min1 mg1
of protein and also normalized to the activity of CS, a mitochon-
drial matrix enzyme, used as a marker of the abundance of mito-
chondria within a tissue.
Lipidomic analysis in mitochondria isolated
frommuscle
For mitochondria lipid extraction, 100 ml aliquots of mitochon-
drial suspension (containing 10 mg of protein) were used for lipid
extraction. Lipids were extracted according to the method of
Bligh and Dyer (99) substituting deuterated dichloromethane
with chloroform (100). Briefly, 320 ll of methanol (MeOH) was
added to each 100 ll sample. Samples were then vortexed for
60 s. Next, 630 ll of DCM was added, the sample was again vor-
texed for 60 s and 200 ll of water was added to induce phase
separation. The samples were then vortexed for 60 s and
allowed to equilibrate at room temperature for 10 min before
centrifugation at 8000g for 10 min at 10 C. A total of 10 ll of the
lower lipid-rich DCM layer was then collected and diluted in
990 ll of acetonitrile (ACN)/DCM/H2O (80:15:5, v/v/v) before
liquid chromatography–mass spectrometry (LC–MS) analysis.
One microliter of sample (equivalent to 200 pg of proteins) was
processed for Nano LC–MS analysis. The LC/MS analyses were
run on an Agilent (Agilent, Santa Clara, CA, USA) 6520 accurate
mass Quadrupole Time-of-Flight (Q-TOF) LC-MS system gov-
erned by Agilent MassHunter software (B.05.00 version). The LC
system consists of a 1200 series high-performance LC (HPLC)
system coupled on-line to MS through a Chip Cube Interface
(Agilent Technologies). Each sample (1 ml) was loaded onto a
large capacity chip-column filled with 3 mm Merck ZIC-HILIC,
integrating a 500 nl capacity trap-column, a 75 mm 150 mm
column, connection capillaries, and a nano-spray emitter.
Solvent A was ACN/DCM/MET/H2O (60:10:10:20, v/v/v/v), con-
taining 5 mM ammonium formate, while solvent B was ACN/
DCM/H2O (80:15:5, v/v/v) containing 5 mM ammonium formate.
Peptides were separated with a linear gradient of 0–100% of solv-
ent A in 30 min at a flow rate of 0.35 ml min1. The LC effluents
were introduced into the Q-TOF spectrometer by Agilent Chip
Cube Interface that operated in negative mode (Vap¼ 1700 V)
with nitrogen as desolvating gas at 325 C and 4.0 l/min; fragmen-
tor, skimmer, and octapole were set at 150, 65 and 750 V, respect-
ively. The Q-TOF operates in MS mode at 2 GHz, extend dynamic
range with two reference ions (mass accuracy 5 ppm, resolution
about 0.05 Da). Mass spectra were acquired in a data-dependent
mode: MS/MS spectra of the five most intense ions were acquired
for each MS scan in the 140–1700 Da range. Scan speed was set to
3 MS spectra s1 and 5 MS/MS spectra s1. Lipid identification and
quantification was performed, after conversion of the raw data in
XML format, by the software LipidXplorer (101).
Histological analyses
The AI and HI were measured in routine H&E-stained muscle
sections (Olympus BX60) from 19 controls (14 males, 5 fe-
males), 15 SBMA patients, 32 ALS patients (26 males, 6 females)
and 14 patients with sensory-motor neuropathies (9 males, 5
females), according to Dubowitz (23), using ImageJ software.
We measured the minor diameter of each fiber (almost 50 fibers
for each muscle sample), because this is not altered by oblique
sectioning or kinking of the fibers. Considering that normal
males have a minor diameter of 40–80 lm (normal females: 30–
70 lm), AI and HI were calculated giving different importance
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to fibers with mild or severe changes in size, using the follow-
ing equations:
Atrophy index ¼ (no. of fibers with a minor diameter
<10 mm) * 4 þ (no. of fibers with a minor diameter of
10–20 mm) * 3 þ (no. of fibers with a minor diameter of 20–
30 mm) * 2 þ (no. of fibers with a minor diameter of 30–40
mm) * 1.
Hypertrophy index ¼ (no. of fibers with a minor diameter
of 80–90 mm) * 1 þ (no. of fibers with a minor diameter of
90–100 mm) * 2 þ (no. of fibers with a minor diameter of
100–110 mm) * 3þ (no. of fibers with a minor diameter
>110 mm) * 4.
These products are divided by the total numbers of fibers
and then multiplied by 1000.
For NADH staining, frozen 8 mm cryosections from five con-
trols and six SBMA patients were brought to room temperature
and then incubated for 40 min at 37 C in 25 ml of 0.2 M Tris/HCl
buffer pH 7.4, 25 ml of distilled water, 25 mg of nitro-blue tetra-
zolium (Sigma N-6876) and 20 mg NADH (Sigma N-8129).
Percentage of dark blue area for field was calculated in the
NADH-stained sections (Olympus BX60) using ImageJ software,
by measuring the number of pixels for field with a dark blue
staining. Briefly, the used procedure divided the image into ob-
jects and background with respect to the threshold set through
Image J (background: low intensity pixels-light blue; object: high
intensity pixels-dark blue). Then, the number of pixels for field
with a value above threshold was measured.
For immunofluorescence (IF) analysis and imaging, 8 mm
muscle cryosections were collected on Superfrost slides, fixed
with 4% paraformaldehyde (PFA), treated with 0.5% Triton-X-
100, blocked in 10% fetal bovine serum in PBS 1X for 30 min and
then incubated overnight at 4 C with primary antibodies,
diluted in blocking solution, against rabbit LC3 (Cell Signaling,
polyclonal, #2775, 1:200) and mouse ATP5A (Abcam, monoclo-
nal, ab110273, 1:200). Each primary antibody was sequentially
incubated separately on the sections. Appropriate secondary
fluorescent antibodies (Alexa-Fluor-488, Invitrogen, A11008,
1:200 for anti-LC3 and Alexa-Fluor-647, Invitrogen, A21235,
1:200 for anti-ATP5A) were used for 1 h at room temperature at
the end of the respective section. Slides were mounted using
Vectashield medium with DAPI stain (Vector) and examined on
a confocal microscope (Leica TCS SP5). In the z-axis stacks
acquired, each image was separated by 0.5 mm along the z-axis.
Using the program Fiji, the number of object-voxel was ana-
lyzed in each green and red slide of the z-stack. Considering the
autophagosoma diameter is about 1 mm, only the voxels equal
to or greater than 1 mm were analyzed. To evaluate the LC3-
ATPase colocalization signal, we used the following formula:ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðx1 x2Þ2 þ ðy1  y2Þ2 þ ðz1 z2Þ2
q
and was considered a
green-red colocalized voxel only when the green voxel (LC3-
autophagosoma) was bigger than the red one (ATPase-
mitochondria).
For transmission electron microscopy, muscle specimens
were fixed in 3.5% glutaraldehyde in 0.1 M sodium-cacodylate
buffer (pH 7.4, room temperature) for 2 h followed by buffer
rinse and post fixation for 1 h in 2% osmium tetroxide. The spe-
cimens were rapidly dehydrated in graded ethanol and acetone,
infiltrated with EPON–acetone (1:1) mixture for 2 h, and
embedded in EPON (102). Ultrathin sections were stained with
uranyl acetate and lead citrate (Reynolds) and examined with a
Philips EM400 transmission electron microscope operating at
100 kV.
Statistical analysis
Data were expressed as mean values6SEM. Statistical differ-
ences of continuous data from two experimental groups were
calculated using Student t tests. Comparisons of data from
more than two groups were performed using a one-way ANOVA
followed by a Fisher’s least significant difference post hoc test.
We considered a P-value<0.05 to be significant.
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